PULIKE BIOLOGICAL ENGINEERING, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 17.2 CNY | -3.86% |
|
-2.11% | -24.06% |
| Sales 2024 * | 1.39B 192M 15.35B | Sales 2025 * | 1.69B 233M 18.64B | Capitalization | 5.83B 805M 64.48B |
|---|---|---|---|---|---|
| Net income 2024 * | 287M 39.61M 3.17B | Net income 2025 * | 340M 46.92M 3.76B | EV / Sales 2024 * | 3.46 x |
| Net cash position 2024 * | 1.03B 142M 11.37B | Net cash position 2025 * | 1.12B 155M 12.39B | EV / Sales 2025 * | 2.8 x |
| P/E ratio 2024 * |
21.9
x | P/E ratio 2025 * |
18.8
x | Employees | 1,718 |
| Yield 2024 * |
3.79% | Yield 2025 * |
4.41% | Free-Float | 51.44% |
More Fundamentals
* Assessed data
More news
| 1 day | -3.86% | ||
| 1 week | -2.11% | ||
| Current month | -1.43% | ||
| 1 month | +3.86% | ||
| 3 months | +4.94% | ||
| 6 months | -11.16% | ||
| Current year | -24.06% |
1 week
16.68
18.20
1 month
16.6018.72
Current year
12.8922.85
1 year
12.8928.80
3 years
12.8934.90
5 years
11.3334.90
10 years
10.5843.25
| Managers | Title | Age | Since |
|---|---|---|---|
Fei Hu
CEO | Chief Executive Officer | 51 | - |
Lian Feng Pei
DFI | Director of Finance/CFO | 51 | 22/03/11 |
Rui Zhao
BRD | Director/Board Member | 40 | 03/05/16 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Yong Chang Cao
BRD | Director/Board Member | 59 | 10/04/23 |
Fei Hu
CEO | Chief Executive Officer | 51 | - |
Xu Ke Zhang
CHM | Chairman | 61 | 22/03/11 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 17.2 | -3.86% | 5,329,256 |
| 25/04/24 | 17.89 | +0.28% | 1,317,800 |
| 24/04/24 | 17.84 | +0.28% | 1,801,400 |
| 23/04/24 | 17.79 | -1.44% | 2,005,800 |
| 22/04/24 | 18.05 | +2.73% | 2,606,300 |
End-of-day quote Shanghai S.E., April 25, 2024
More quotes
Pulike Biological Engineering. Inc is principally engaged in the research, development, production and distribution of veterinary biological products and chemical medicines. The Company's veterinary biological products include vaccine and antibody, applied in the prevention and controlling of infection to epidemic disease for poultry and livestock. Its veterinary chemical medicines are mainly used in the treatment of epidemic diseases of poultry and livestock.
Sector
Pharmaceuticals
Calendar
21/08/2024
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.2
CNY
Average target price
18.97
CNY
Spread / Average Target
+10.29%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -24.06% | 805M | |
| -19.73% | 72.39B | |
| -11.01% | 6.54B | |
| +15.88% | 3.43B | |
| -0.68% | 1.4B | |
| -17.27% | 1.34B | |
| -2.73% | 1.26B | |
| -28.16% | 1.2B | |
| -14.67% | 1.12B | |
| -5.37% | 990M |
- Stock Market
- Equities
- 603566 Stock
